Hereditary Spastic Paraplegia Market
Number of pages: 100 | Report Format: PDF | Published date: March 29, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
6.7% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global hereditary spastic paraplegia market is expected to register a revenue CAGR of 6.7% during the forecast period from 2023 to 2031.
Market Fundamentals
Hereditary spastic paraplegias (HSPs) are a group of monogenic neurological abnormalities that cause corticospinal and posterior spinal cord axonal atrophy, with a global frequency of 0.1-9.6 cases per 100,000 people. A set of clinically and genetically diverse neurodegenerative disorders marked by increasing stiffness and weakening of the lower limbs are together referred to as hereditary spastic paraplegias (HSP). Subsequently, there are presently no effective treatments for hereditary spastic paraplegias; symptoms are only managed by lowering muscle stiffness and enhancing strength and gait. Physical therapy, oral skeletal muscle relaxants such as baclofen, progabide, dalfampridine, botulinum toxin therapy, and surgical baclofen pump implantation are all available as treatments. However, there are currently no evidence-based recommendations or guidelines available to doctors to assist them in choosing the best course of treatment, and up to this point, no critical evaluation of the therapeutic arsenal has been offered.
Complex symptomatic therapies for hereditary spastic paraplegias require ongoing patient and caregiver involvement. Implementing rehabilitative therapies is the first stage in creating compensatory mechanisms and preserving functions. A multidisciplinary team is necessary for patient evaluation and management over the long term, ideally up to palliative care. Several ongoing research and developments are involved in inventing novel therapeutics to treat hereditary spastic paraplegias. A gene-specific treatment for hereditary spastic paraplegias has not yet been created, although physio-pathological research using animal models or neurons made from induced pluripotent stem cells has identified some promising targets for treatment. Recently, a replacement therapy was studied by giving CYP7B1 mRNA to a mouse model with a genetic knockout. The levels of 25-hydroxycholesterol were significantly lower in the liver, serum, and brain 48 hours after the injection of a mouse or human CYP7B1 mRNA, whereas the levels of 27-hydroxycholesterol were reduced exclusively in the serum. Thus, a strong pipeline and advanced research influence the revenue growth of the global hereditary spastic paraplegias market.
Market Dynamics
The market revenue is expected to grow more rapidly as autoimmune illnesses become more prevalent. The factors for developing hereditary spastic paraplegia are autoimmune diseases, trauma, and cerebral palsy. According to the Atlas of Multiple Sclerosis Report from 2020, more than 2.8 million people live with multiple sclerosis globally, including about 1 million in the United States. The prevalence of autoimmune diseases is rising, which is a worry for developed countries. Myelin breakdown and axonal degeneration, which are influenced by hereditary and environmental factors, are this disease's most prevalent pathologic hallmarks. Even though autoimmune disorders are uncommon, certain of them frequently co-occur, such as hereditary spastic paraplegia. The growing population, which is more susceptible to certain hereditary spastic paraplegia, is another factor driving up adoption rates of advanced diagnostics, which increases the quality of treatment. Growing public understanding of the benefits of early diagnosis and the availability of MRI-compatible pacemakers also boosts the hereditary spastic paraplegia market. Additionally, government initiatives and the expanding healthcare sector are expected to stimulate market revenue growth by enhancing access to high-quality healthcare facilities. Increased public awareness of the disease and the benefits of its therapy will boost the likelihood of early diagnosis and, as a result, the rate of treatment. For instance, The Spastic Paraplegia Foundation organized Hereditary Spastic Paraplegia (HSP) and Primary Lateral Sclerosis (PLS) awareness week from 21-28th August 2022. A confluence of events and increased patient advocacy group (PAG) activity have raised public awareness of rare hereditary diseases. Funding constraints prevent comprehensive research, which results in a dearth of effective medicines and a protracted diagnostic journey.
The market is expected to be driven by upcoming biotechnological products, such as gene therapy for treating hereditary spastic paraplegia. Understanding the function of significant genes has been made possible by recent developments in the technology that may be used to investigate the composition, structure, and localization of genes.
However, the high treatment cost and lack of proper therapeutics with stringent regulation for drug approval are the major restraining factors limiting revenue growth of the global hereditary spastic paraplegia market. Further, the complication related to the treatment and lack of proper early diagnostics; the disease remains undetected, which is responsible for hampering the market revenue growth to a certain extent.
Market Ecosystem
The global hereditary spastic paraplegia market is analyzed from three perspectives: drug class, distribution channel, and region.
Hereditary Spastic Paraplegia Market by Drug Class
[45645]
Based on the drug class, the global hereditary spastic paraplegia market is segmented as skeletal muscle relaxants, anxiolytics, benzodiazepines, and nonsteroidal anti-inflammatory drugs (NSAIDs). The skeletal muscle relaxants are further sub-segmented as baclofen, tizanidine, dantrolene sodium, and onabotulinumtoxinA.
The skeletal muscle relaxants segment accounted for the largest revenue share of the global hereditary spastic paraplegia market in 2022. There are no specific treatments currently that can cease, slow down, or reverse the progressive impairment in hereditary spastic paraplegia. The only goal of treatment is to lessen muscle stiffness and urine urgency while enhancing strength and step. Treatment options include botulinum toxin therapy, surgical baclofen pump implantation, and oral skeletal muscle relaxants such as baclofen, progabide, and dalfampridine. Skeletal muscle relaxants are the irst line of treatment for hereditary spastic paraplegia. Myorelaxants, commonly called muscle relaxants, are a wide class of pharmacological substances that can relax skeletal muscle. These medications belong to a different class and are used during intubations and surgery to ease the intubation process and lessen the requirement for anesthesia. In neuromuscular illnesses, skeletal muscle relaxants are also used to treat spasticity. Antispasmodic skeletal muscle relaxant drugs often work by directly affecting the spinal cord or skeletal muscles to reduce muscle tension (hypertonicity) and uncontrollable spasms helping in the rapid pain relief and long-lasting effect.
Hereditary Spastic Paraplegia Market by Distribution Channel
Based on the distribution channel, the global hereditary spastic paraplegia market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies segment accounted for the largest revenue share of the global Hereditary Spastic Paraplegia market in 2022. Hospital pharmacies play an important role in the care of rare illnesses and substantially impact the growth of the hereditary spastic paraplegia market. Hospital pharmacies have several advantages that help the market revenue thrive. Patients can acquire a greater range of medications from hospital pharmacies, including biologics that may not be available elsewhere. As a result, patients may obtain the best possible treatment for their conditions. Furthermore, hospital pharmacies can work closely with other medical specialists to provide coordinated and tailored therapy to patients suffering from acute febrile neutrophilic dermatosis syndrome. This could lead to improved treatment outcomes and patient satisfaction. These pharmacies might instruct customers on how to use their medications properly, improve prescription adherence, and reduce the possibility of side effects.
The hospital pharmacy can also keep an eye on patients medicines and help with any side effects or other problems that may arise during treatment. This can help to guarantee that patients get the finest care available and that treatment results improve. Additionally, these pharmacies are qualified to take part in research trials. By participating in clinical studies, pharmacies can also access the latest findings in research and treatment options, which can improve patient outcomes. Moreover, participating in clinical studies could enhance their reputation and draw in new patients. Furthermore, various government programs, including the subsidized medicine program, assist patients in purchasing costly therapies for rare ailments regardless of their financial circumstances. Due to rising prescription costs and the dearth of pharmaceuticals in retail pharmacies, people now prefer hospital pharmacies, which has significantly increased revenue. Hospital pharmacies have also invested in technology to enhance patient care and safety, including computerized drug administration records and automated dispensing systems. These developments have helped hospital pharmacies gain more and more favor with patients.
Hereditary Spastic Paraplegia Market by Region
Based on the region, the global hereditary spastic paraplegia market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America accounted for the largest revenue share of the global hereditary spastic paraplegia market in 2022. The increased prevalence of rare diseases such as hereditary spastic paraplegia in North America is the main factor propelling the growth of the global market revenue. The rise in awareness and diagnosis of rare diseases is also contributing to revenue growth due to more patients seeking treatment options and pharmaceutical companies investing in research and development for these conditions. Additionally, technological advancements and personalized medicine are creating new opportunities for targeted therapies for rare diseases. The hereditary spastic paraplegia market in North America is expected to experience significant revenue growth. This growth is likely to be driven by an increase in diagnosed cases and treatment options advancements. In addition, the increasing prevalence of chronic diseases and the growing aging population are also contributing factors to revenue growth of the global market in North America. Furthermore, favorable government policies and initiatives to improve healthcare infrastructure is expected to drive market revenue growth in the region.
The Asia Pacific hereditary spastic paraplegia market is expected to register a significant revenue growth during the forecast period due to the rising prevalence of hereditary spastic paraplegia and increasing healthcare expenditure in the region. Moreover, the presence of key market players and ongoing research and development activities are also contributing to revenue growth of this market.
Competitive Landscape
Hereditary spastic paraplegia (HSPs) is a rare, inherited neurological illness with wide clinical and genetic variability.
Increased autoimmune diseases and advanced research & development are the key factors influencing the growth of the hereditary spastic paraplegia market.
Lack of knowledge about the diseases and proper diagnostics for early detection are likely to hinder the growth of the global hereditary spastic paraplegia market during the forecast period.
Key companies operating the global Hereditary Spastic Paraplegia market are Novartis AG, Intas Pharmaceuticals Limited, Amneal Pharmaceuticals, Inc., SUN PHARMACEUTICAL INDUSTRIES LTD., and Chemo Biological.
The global hereditary spastic paraplegia market is expected to grow at a revenue CAGR of 6.7% during the forecast period from 2023 to 2031.
*Insights on financial performance are subject to the availability of information in the public domain